Cyclerion pharmaceuticals
WebApr 3, 2024 · Cyclerion Therapeutics, a clinical-stage biopharma, announced Monday morning that it is in negotiations with its CEO Peter Hecht about a $5 million equity investment in the company. Per a press release, Cyclerion has entered into a binding agreement with Hecht to make an equity investment for common stock or nonvoting … WebCyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate.
Cyclerion pharmaceuticals
Did you know?
WebAug 9, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’s lead molecule … WebJun 4, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class,...
WebBoston, Massachusetts Type Privately Held Founded 2024 Specialties Biotechnology, Therapeutics, Cardiovascular, Heart Failure, and Cardiology Locations Primary 31 St James Ave Sixth Floor Boston,... WebCyclerion 3 years 10 months Vice President, Clinical Strategy Dec 2024 - Present1 year 2 months Senior Director, Clinical Strategy Jan 2024 - …
WebJan 4, 2024 · – Mark Mallon to become CEO of Ironwood – – Peter Hecht, founder and current CEO of Ironwood, to become CEO of Cyclerion (R&D Co.) – Jan. 4, 2024- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective … WebCNS vascular pathology – impaired blood flow, inflammation, endothelial dysfunction, small vessel disease CY6463 Pharmacology Preclinical data suggest CY6463 has the …
WebApr 12, 2024 · The main competitors of Cyclerion Therapeutics include AgeX Therapeutics (AGE), Impel Pharmaceuticals (IMPL), NightHawk Biosciences (NHWK), Bionomics …
WebApr 1, 2024 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble... popup aktivieren windows 10Webcyclerion.gcs-web.com pop up airsoftWebJul 9, 2024 · Presenter SpeechPeter Hecht Okay, great. Let's get started. Good morning. Welcome to our CNS-Focused Investor Event. We're pleased to have you join us. Today's webinar is going to be centered on... 14 April 2024 popup agency qatarWebApr 1, 2024 · About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company focused on creating medicines that make a … sharon hudson-deanWebChairman Of The Board at Cyclerion Winchester, Massachusetts, United States 697 followers 500+ connections Join to view profile Cyclerion Experience Chairman Of The Board Cyclerion 2024 -... sharon hudson deanWebJoe has acted as portfolio and transaction manager for several corporate clients including Sage Therapeutics, Ironwood, Cyclerion, A123 Systems, ARIAD Pharmaceuticals, Biogen, Boston Scientific ... sharon hudson modelWebCyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough … sharon hudson obituary